VBL Therapeutics VB-111 Showed Significant Increase In Overall Survival At Therapeutic vs. Low Dose Level, 60% Durable Repsonse Rate; Trial Designed To Evaluate Safety, Tolerability, and Explore Efficacy
Paul Quintaro